60 Degrees Pharmaceuticals, Inc. is facing potential delisting from The Nasdaq Capital Market after receiving a notification from Nasdaq regarding its failure to meet minimum bid price requirements. The company’s stock price has been below $1.00 per share for over 30 consecutive business days, prompting the Nasdaq Listing Qualifications Department to take action. This situation is significant as it reflects ongoing challenges for smaller companies in the pharmaceutical preparations industry.
According to the recent SEC filing dated November 20, 2026, the company received a letter from Nasdaq on November 19, 2026. The letter indicated that the company did not comply with the minimum bid price requirement outlined in Nasdaq Listing Rule 5550(a)(2). This rule mandates that listed securities maintain a minimum bid price of $1.00.
60 Degrees Pharmaceuticals, which operates under the ticker symbols SXTP and SXTPW on Nasdaq, has previously undergone multiple reverse stock splits, including a 1-for-5 split in February 2025 and a 1-for-4 split in January 2026. As a result of these actions, the company is currently ineligible for any compliance period, as stipulated by Nasdaq Listing Rule 5810(c)(3)(A).
In the filing, the company stated, "Unless the Company requests an appeal of Staff’s determination by November 27, 2026, the Company’s securities will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on December 1, 2026." This means that the company has a limited window to take action to avoid delisting.
60 Degrees Pharmaceuticals has confirmed that it will appeal the Nasdaq staff determination and has paid the required $20,000 hearing fee. This appeal will temporarily stay the suspension of trading and the filing of the Form 25-NSE, which is necessary for delisting. The company will need to present a plan to regain compliance during the hearing, which may include additional reverse stock splits.
The filing further notes that the company plans to execute a reverse stock split effective December 2, 2026. This move is aimed at increasing the per-share bid price of its common stock to meet Nasdaq's requirements. The company expects that its common stock will begin trading on a split-adjusted basis under the existing trading symbol “SXTP.” However, there is no guarantee that this action will suffice to regain compliance or that the Panel will grant the company’s request for continued listing.
As of now, the company is under pressure to demonstrate its viability and compliance to avoid being delisted. This situation not only affects the company but also has implications for investors and stakeholders who are closely monitoring its next steps. The pharmaceutical preparations industry, particularly for smaller firms like 60 Degrees Pharmaceuticals, often faces heightened scrutiny and challenges in maintaining compliance with market regulations.
Looking ahead, the company’s next steps will involve the appeal process and the execution of the planned reverse stock split. The outcome of these actions will be crucial in determining whether 60 Degrees Pharmaceuticals can continue to operate on the Nasdaq platform.
Read Next
Alps Group Regains Compliance with Nasdaq Listing Standards
Ainos, Inc. Receives Nasdaq Delisting Notice Over Equity
Compass Therapeutics Receives Nasdaq Deficiency Notice
Biofrontera Inc. Faces Nasdaq Delisting Due to Low Stock Price
Senti Biosciences dismisses KPMG, appoints new auditor KNAV
Presidio Property Trust announces transfer of stock listing










